Bcl-2 or Bcl-X L confers resistance to chemotherapy in multiple myeloma (MM). Here we characterized the effects of ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-X L and Bcl-w with markedly higher affinity than previously reported compounds, on human MM cells. ABT-737 induces apoptosis in MM cells, including those resistant to conventional therapy. Examination of purified patient MM cells demonstrated similar results, without significant toxicity against normal peripheral blood mononuclear cells and MM bone marrow stromal cells. Importantly, ABT-737 decreases the viability of bortezomib-, dexamethasone-(Dex) and thalidomide-refractory patient MM cells. Additionally, ABT-737 abrogates MM cell growth triggered by interleukin-6 or insulin-like growth factor-1. Mechanistic studies show that ABT-737-induced apoptosis is associated with activation of caspase-8, caspase-9 and caspase-3, followed by poly(ADP-ribose) polymerase cleavage. Combining ABT-737 with proteasome inhibitor bortezomib, melphalan or dexamethasone induces additive anti-MM activity. Taken together, our study provides the rationale for clinical protocols evaluating ABT-737, alone and together with botezomib, mephalan or dexamethasone, to enhance MM cell killing, overcome drug resistance conferred by Bcl-2 and improve patient outcome in MM.
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Oncogene ( Keywords: multiple myeloma; mitochondria; apoptosis; Bcl-2 Chemotherapy triggers growth arrest and apoptosis in cancer cells (Willie et al., 1980) , and mitochondrial signaling is an important component of chemotherapyinduced apoptosis (Bossy-Wetzel and Green, 1999; Dalton, 2002) . The Bcl-2 family of proteins regulate, in part, the release of mitochondrial apoptogenic factors such as cytochrome-c (cyto-c) into the cytosol, thereby modulating caspase-9-mediated cell-death signaling cascade (Kluck and Kashibatta, 1997) . Functional categorization of Bcl-2 proteins shows two distinct groups based on their proapoptotic (Bax, Bak, Bad, Bik) or antiapototic (Bcl-2, Bcl-X L , Bcl-w) activities (Cory and Adams, 2005) . Both proapoptotic and antiapoptotic family members are a-helical proteins with structural and sequence similarity (Petros et al., 2004) . Additionally, the proapoptotic Bcl-2 family members Bid and Bad have only a single-a-helix BH-3 region. Under stress, BH-3-only proteins initiate apoptosis by either blocking the activity of antiapoptotic members or directly activating proapoptotic members (Cory and Adams, 2005) , which is mediated via the interaction of BH-3 a-helix of one protein with a hydrophobic pocket of the other (Cory and Adams, 2005) . Identification of BH3-mimetic drugs that inactivate specific prosurvival targets and/or trigger apoptotic signaling by interfering with the interaction of Bcl-2 proteins may therefore be therapeutically useful, since Bcl-2 activity is highly elevated and confers drug resistance in many cancer cells (Gazitt et al., 1998; Liston et al., 2003) .
A recent study demonstrates that Bc1-2 antisense oligodeoxynucleotide, downregulates expression of Bcl-2 and enhances sensitivity to Dex-, paclitaxel and Doxorubicin-induced apoptosis in multiple myeloma (MM) cells (Liu and Gazitt, 2003; van de Donk et al., 2003) . Our prior study showed that peptides targeting the BH3 domain of Bcl-2 enhance bortezomib-induced apoptosis, whereas overexpression of Bcl-2 inhibits Bid cleavage and associated apoptosis (Mitsiades et al., 2003) . Nonetheless, the clinical utility of these inhibitors has been limited due to issues of half-life/stability and/or specificity. Recently, Oltersdorf et al. (2005) have utilized nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design to identify ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-X L and Bcl-w with an affinity 2-3 orders of magnitude more potent than any previously reported compounds (Degterev et al., 2001; Cory and Adams, 2005) . Importantly, ABT-737 disrupts intracellular Bcl-2 protein-protein interaction in a mammalian two-hybrid system (Cory and Adams, 2005; Oltersdorf et al., 2005) , further supporting its evaluation for therapeutic use. In the present study, we characterized the antitumor activity of ABT-737 against MM cell lines and primary patient MM cells resistant to conventional therapies.
We first determined whether ABT-737 affects the viability in MM cells. ABT-737 treatment (48 h) of MM cell lines (MM.1S, OPM1, KMS-12PE, INA-6, KMS-12BM, MC/CAR), as well as those resistant to conventional anti-MM agents Dex (MM.1R), Dox (Dox-40) or melphalan (LR-5), induces a dose-dependent significant (Po0.005, n ¼ 3) decrease in viability in all cell lines (IC 50 range 2-12 mM) (Figure 1a) . The functional specificity of ABT-737 binding to Bcl-2 or Bcl-X L was confirmed by using the less active enantiomer of ABT-737, which had no significant effect on viability of MM.1S cells, even at higher concentration ( Figure 1a) . To determine whether ABT-737-induced decreased MM cell viability is due to apoptosis, we examined whether ABT-737 triggers morphological changes characteristic of apoptosis. Chromatin condensation and nuclear disintegration are typical signs of apoptotic cell death. MM.1S cells treated with ABT-737 (2 mM) for 48 h show a marked increase in nuclear condensation, as indicated (Oberhammer et al., 1994) .
ABT-737 triggered similar effects in patient MM cells: Purified (CD138-positive) MM cells from five patients relapsing after multiple prior therapies including Dex (Figure 1c , Pt#1), bortezomib (Pt#2 and 3) and thalidomide (Pt#4 and #5) were treated for 48 h with ABT-737 (2-8 mM), and then analysed for viability. A significant decrease in viability of all patient MM cells was noted in response to treatment with ABT-737 (Po0.004) (Figure 1c) . Importantly, two of four patients studied were refractory to bortezomib therapy and three were resistant to thalidomide and Dex therapies. The decrease in MM patient cell viability was due to apoptosis in these cells as evidenced by DNA fragmentation (Figure 1d , Po0.005) and PARP cleavage (Inset). Our findings using MM cells are in concert with an earlier study suggesting single-agent activity of ABT-737 against lymphoid malignancies and small-cell lung cancer cells (Oltersdorf et al., 2005) . These results suggest that inhibition of Bcl-2 family proteins using ABT-737 alone is sufficient to block the growth and trigger apoptosis in MM cells.
Stress stimuli trigger alternative compensatory mechanisms to maintain homeostasis. To exclude the possibility that Bcl-2 inhibition is a reversible event, we performed washout experiment. MM.1S cells were treated with ABT-737 (2 and 4 mM) for 3 or 6 h, then the medium containing ABT-737 was removed, and viability was assessed at 48 h after the initiation of the experiment (Figure 2a) . The decrease in viability of MM.1S cells was noted after 3 h of ABT-737 exposure. After 6 h of exposure, the decrease in MM.1S cell viability was similar to that observed for continuous 48 h of exposure. These data show that treatment of MM cells with ABT-737 cause an early and irreversible commitment to cell death.
We next examined whether ABT-737 affects the viability of normal peripheral blood mononuclear cell (PBMCs) and MM-derived bone marrow stromal cells (BMSCs) Normal lymphocytes from four healthy donors (Nr#1-Nr#4, Figure 2b ) were treated with ABT-737 (2-8 mM) and analysed for viability. ABT-737 does not significantly decrease the viability of normal PBMCs at these concentrations (P ¼ 0.26 from J to T trend test) (Figure 2b ). Higher concentrations of ABT-737 (10-15 mM) decrease viability of lymphocytes by 2472.5%, indicating that normal cells are not completely refractory to ABT-737. Nonetheless, these data suggest a therapeutic index for ABT-737. Besides normal lymphocytes, we also examined the effect of ABT-737 on cells present within the BM microenviroment. The interaction of MM cells with BM stromal cells (BMSCs) induces cytokine secretion, which mediates paracrine growth of MM cells as well as protects against drug-induced apoptosis (Chauhan et al., 2005b) . Importantly, ABT-737 does not induce apoptosis in MM BMSCs (Figure 2c ). As a positive control, ABT-737-triggered apoptosis in purified patient tumor cells (MM #1 and MM #2) (Figure 2c ). Taken together, these findings confirm the selective anti-MM activity of ABT-737. Previous studies showed that cytokines present within the MM bone marrow (BM) microenvironment mediate growth/survival and confer drug resistance in MM cells (Chauhan et al., 2005b) . For example, interleukin-6 (IL-6) and insulin-like growth factor-I (IGF-I) induce growth and protect against chemotherapy-induced apoptosis in MM cells in vitro (Hardin et al., 1994; Jelinek et al., 1997; Xu et al., 1997) . High serum levels of IL-6 or IGF-I contribute to clinical chemoresistance and treatment failure in MM (Chauhan et al., 2005b) . We therefore next asked whether IL-6 or IGF-I affects ABT-737-induced apoptosis in MM cells. Neither IL-6 nor IGF-I block ABT-737-triggered cytotoxicity in MM.1S cells (Figure 2d ). As a positive control, both IL-6 and IGF-I block Dex-induced decreases in MM.1S cell viability. Taken together, these findings show that ABT-737, unlike Dex, is able to inhibit cytokine-induced MM cell growth.
We next examined the mechanisms mediating anti-MM activity of ABT-737. Bcl-2 protein is predominantly localized in the outer mitochondrial membrane and regulate, in part, the release of mitochondrial apoptogenic factors such as cyto-c into the cytosol, thereby modulating intrinsic apoptotic signaling pathway via caspase-9 (Kluck and Kashibatta, 1997). We therefore examined whether inhibition of Bcl-2 activity by ABT-737 results in activation of caspase-9>caspase- 
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Bcl-2 results in caspase-8 activation is unclear. However, previous studies using other cell systems showed that caspase-8 activation can occur upstream and also downstream of mitochondria in a feedback amplification loop (Fulda et al., 2002) . It is likely that ABT-737-triggered caspase-9>caspase-3 signaling leads to caspase-8 activation in MM cells. Another possibility is that ABT-737 affects TNF-associated death domain complexes, leading to caspase-8 activation. Nonetheless, our findings suggest that ABT-737 may facilitate crosstalk between the intrinsic and extrinsic apoptotic signaling pathways.
One mechanism whereby Bcl-2 inhibits apoptosis is by blocking the release of cyto-c from mitochondria to cytosol (Yang et al., 1997) . We therefore next determined whether inhibition of Bcl-2 using ABT-737 results in cyto-c release. Our results show that ABT-737-induced apoptosis in MM cells is associated with the release of cyto-c, as evidenced by an increase in cyto-c content in the cytosolic fraction and a concurrent decrease in mitochondrial cyto-c (Figure 3b , lower panel). Bcl-2 also acts upstream of proapoptotic protein Bax and prevents activation by intercepting activator BH-3 molecules. ABT-737 has the ability to displace BH-3 activator molecules and allow Bax activation and cyto-c release (Certo et al., 2006) . In agreement with these findings, ABT-737 triggered significant cell death in Bax (wt) (5371.3%), but not in Bax-knockout (1170.8%) cells. Importantly, a recent study also showed that ABT-737 binds to and inhibits antiapoptotic Bcl-2 family proteins, but does not directly activate proapoptotic Bax and Bak (Oltersdorf et al., 2005; Certo et al., 2006) . Together, these findings provide evidence that ABT-737 is a Bcl-2 antagonist.
A previous study showed that ABT-737 binds Bcl-2, Bcl-x L and Bcl-w with high affinity, but has far lower affinity for Mcl-1 (Oltersdorf et al., 2005) . Thus, the antitumor activity of ABT-737 may depend on the relative expression of the prosurvival proteins. We therefore examined whether Bcl-2 expression levels correlate with sensitivity to ABT-737. For these studies, we selected MM.1S (sensitive to ABT-737: IC 50 -2 mM) and OPM-1 (least sensitive to ABT-737; IC 50 : 10-15 mM) and examined the basal expression levels of Bcl-2, Bcl-x L and Mcl-1. MM.1S cells, in contrast to OPM-1 cells, express high basal levels of both Bcl-2 and Bcl-x L , but low Mcl-1 protein; conversely, OPM-1 cells express high Mcl-1 and low Bcl-2 levels (Figure 3c , upper three panels). As ABT-737 cannot neutralize Mcl-1, it is likely that the high Mcl-1 and low Bcl-2/Bcl-xL expression profile in OPM-1 renders these cells less sensitive to ABT-737; whereas, low Mcl-1 and high Bcl-2/Bcl-xL expression in MM.1S cells allows for efficient killing by ABT-737. Additionally, higher protein expression of proapoptotic Bcl-2 family member Bim were detected in MM.1S cells than in OPM-1 cells; Bim is known to trigger Bax/Bak oligomerization, a key event during mitochondrial apoptotic signaling. Taken together, these finding suggest that (1) sensitivity to ABT-737 correlates with Bcl-2 expression in MM cells, (2) higher expression of Mcl-1 may result in lesser sensitivity to Bcl-2 inhibition by ABT-737 and (3) small molecules and other anti-MM agents that downregulate or block Mcl-1 may synergize with ABT-737.
Bcl-2 is linked to p53-mediated signaling, and we therefore next examined whether ABT-737 is able to overcome the tumorigenic effects conferred by mutation in p53 in MM cells. For these studies, we again selected MM.1S (sensitive to ABT-737: IC 50 -2 mM) and OPM-1 (least sensitive to ABT-737; IC 50 : 10-15 mM) and examined p53 status. Coprecipitations and immunoblotting experiments show that MM.1S cells predominantly carry wild-type p53, whereas OPM-1 cell line has mutated p53 (Figure 3d) . Additional experiments using KMS-12PE and KMS-12BM (IC 50 ¼ 0.8 mM at 24 h for both cell lines) showed predominant expression of p53 (wt) (data not shown). Our findings suggest that ABT-737 induces killing even in MM cells carrying p53 mutation, albeit at higher concentrations. Importantly, only 5-10% of MM patients have p53 mutations, and the majority has wt-p53. Our ongoing studies are further evaluating this issue using inducible p53 knockouts and/ or knock-in models in MM. Nonetheless, our present findings provide evidence for the anti-MM activity of ABT-737 in MM with p53 (wt) or p53 (mt), albeit with differential sensitivity.
Having shown the single agent anti-MM activity of ABT-737, we next examined whether it can be combined with other drugs to enhance cytotoxicity. MM.1S MM cells were treated with both ABT-737 and/or conventional anti-MM agent dexamethasone (Dex) and analysed for viability. ABT-737 þ Dex triggered additive anti-MM activity, evidenced by a significant decrease in viability of MM.1S cells (Figure 4a ). Isobologram analysis (Chou and Talalay, 1984) confirmed additive anti-MM activity of ABT-737 and Dex (combination index (CI) ¼ 1.0 (Po0.05, n ¼ 3)). Our results are consistent with a recent study showing enhanced anti-MM activity between Dex and Bcl-2 antisense oligonucleotides (Liu and Gazitt, 2003) . To further explore this issue, we combined ABT-737 with another commonly used anti-MM drug melphalan and examined their effect on MM cells viability. Treatment of MM.1S MM cells with ABT-737 significantly enhances the antitumor activity of melphalan (CI ¼ 1.0; Po0.05, n ¼ 3) (Figure 4b ). Combined ABT-737 þ melphalan also decreased the viability of purified patient MM cells (data not shown). Our findings are consistent with a previous report showing the ability of ABT-737 to enhance the antitumor activity of chemotherapeutic agents (paclitaxel, etoposide, doxorubicin, cisplatin) against solid tumor cells (Oltersdorf et al., 2005) .
ABT-737 binds Bcl-x L , Bcl-2 and Bcl-w with high affinity, but has far lower affinity for other prosurvival proteins Mcl-1 and A1 (Oltersdorf et al., 2005) . Importantly, Mcl-1 is overexpressed in MM cells and its expression correlates with shorter survival in these patients (Le Gouill et al., 2004; Wuilleme-Toumi et al., 2005) . Our data also suggest that OPM-1 cells have higher levels of Mcl-1 than Bcl-2 and are relatively less sensitive to treatment with ABT-737 (Figure 1 and 3c ). These observations suggest that combining ABT-737 Adams, 2005) , and a recent study showed that proteasome inhibitor bortezomib/Velcade induces Noxa expression in MM cells (Qin et al., 2005; Perez-Galan et al., 2006) . We therefore examined whether combining ABT-737 with bortezomib trigger additive anti-MM activity. Treatment of MM.1S MM cells with ABT-737 and bortezomib induces additive cytotoxicity (Figure 4c , CI ¼ 1.0). The mechanism underlying additive anti-MM activity of ABT-737 with bortezomib may include downregulation of Mcl-1 along with Bcl-2; however, additional proapoptotic signaling cannot be ruled out and remains to be defined. Nonetheless, our findings have clinical implications: bortezomib is FDA approved for the treatment of relapsed and/ or refractory MM, but prolonged treatment can be associated with toxicity (Chauhan et al., 2005a, b) ; and combining ABT-737 with bortezomib would allow for the use of lower doses of bortezomib. To exclude the possibility that this event is specific to bortezomib, we performed experiments using another proteasome inhibitor MG-132. MM.1S cell were treated with ABT-737 (1 mM) and MG 132 (50 nM) for 24 h and then analysed for viability. Treatment of MM.1S cells with either ABT-737 or MG-132 triggered minimal decrease in viability in these cells, whereas ABT-737 þ MG132 induced significant decrease in viability cells (Figure 4d , Po0.005, n ¼ 3). Taken together, these data suggest that ABT-737 enhances the antitumor activity of both conventional and novel anti-MM agents, which may allow for use of lower doses and thereby reduce toxicities. Collectively, our study shows the following: (1) ABT-737 induces apoptosis in MM cells resistant to conventional and bortezomib therapies at concentrations that do not affect normal PBMCs viability; (2) ABT-737 does not affect MM-derived BMSC viability; (3) ABT-737 induces MM cell apoptosis even in the presence of MM growth factors, such as IL-6 or IGF-1; (4) ABT-737-induced apoptosis in MM cells is associated with activation of caspases-8, -9 and -3 and finally, (5) combinations of low doses of ABT-737 and melphalan, Dex or bortezomib trigger additive anti-MM activity. A report that ABT-737 enhances the apoptotic activity of chemotherapeutic agents (Oltersdorf et al., 2005) , together with our present findings, provides the framework for clinical trials of ABT-737, either alone or in combination with other anti-MM agents, to enhance efficacy, reduce toxicity and overcome drug resistance in patients with relapsed/refractory MM.
